TICKERNOMICS Sign up
Last Update: 2024-12-27 15:27:59
bluebird bio Inc. ( BLUE ) https://www.bluebirdbio.com
8.78USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
27.80%
-68.87%
BLUE
SPY
32.66%
-95.92%
BLUE
SPY
108.59%
-99.23%
BLUE
SPY
302.52%
-99.27%
BLUE
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1648.09
1770.01
0.36
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-5.48
31.03
-284.84
-11.82
0.00
-7.43
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-630.60
-11.02
-426.20
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
7.9632
-51.29
-71.16
0.99
Other Earnings and Cash Flow Stats:
bluebird bio Inc. ( BLUE ) Net Income TTM ($MM) is -300.52
bluebird bio Inc. ( BLUE ) Operating Income TTM ($MM) is -316.68
bluebird bio Inc. ( BLUE ) Owners' Earnings Annual ($MM) is 0.00
bluebird bio Inc. ( BLUE ) Current Price to Owners' Earnings ratio is 0.00
bluebird bio Inc. ( BLUE ) EBITDA TTM ($MM) is -243.94
bluebird bio Inc. ( BLUE ) EBITDA Margin is -426.20%
Capital Allocation:
bluebird bio Inc. ( BLUE ) has paid 0.00 dividends per share and bought back -84.795 million shares in the past 12 months
bluebird bio Inc. ( BLUE ) has reduced its debt by 111.14 million USD in the last 12 months
Capital Structure:
bluebird bio Inc. ( BLUE ) Interest-bearing Debt ($MM) as of last quarter is 192
bluebird bio Inc. ( BLUE ) Annual Working Capital Investments ($MM) are 15
bluebird bio Inc. ( BLUE ) Book Value ($MM) as of last quarter is -6
bluebird bio Inc. ( BLUE ) Debt/Capital as of last quarter is -3329%
Other Balance Sheet Stats:
bluebird bio Inc. ( BLUE ) has 70 million in cash on hand as of last quarter
bluebird bio Inc. ( BLUE ) has 296 million of liabilities due within 12 months, and long term debt 70 as of last quarter
bluebird bio Inc. ( BLUE ) has 193 common shares outstanding as of last quarter
bluebird bio Inc. ( BLUE ) has 0 million USD of preferred stock value
Academic Scores:
bluebird bio Inc. ( BLUE ) Altman Z-Score is -13.75 as of last quarter
bluebird bio Inc. ( BLUE ) Piotroski Score is 2.00 as of last quarter
Corporate Governance:
bluebird bio Inc. ( BLUE ) largest shareholder is owning shares at 0.00 ($MM) value
Obenshain Andrew(an insider) Sold 971 shares of bluebird bio Inc. ( BLUE ) for the amount of $405.20 on 2024-12-10
0.63% of bluebird bio Inc. ( BLUE ) is held by insiders, and 43.69% is held by institutions
bluebird bio Inc. ( BLUE ) went public on 2013-06-19
Other bluebird bio Inc. ( BLUE ) financial metrics:
FCF:-231.02
Unlevered Free Cash Flow:0.00
EPS:-0.06
Operating Margin:-630.60
Gross Profit Margin:-11.02
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:4203.80
Beta:0.99
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About bluebird bio Inc. ( BLUE ) :
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.